Literature DB >> 8630098

Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase.

X Xiong1, J L Smith, C Kim, E S Huang, M S Chen.   

Abstract

Cidofovir [CDV,(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] is an acyclic cytosine nucleoside phosphonate analog with potent in vitro and in vivo activity against a broad spectrum of herpesviruses. CDV diphosphate (CDVpp), the putative antiviral metabolite of CDV, is a competitive inhibitor of dCTP and an alternate substrate for human cytomegalovirus (HCMV) DNA polymerase. HCMV DNA polymerase used a synthetic DNA primer-template with a Km value of 90 +/- 8 nM and incorporated dCTP approximately 42 times more efficiently than CDVpp. HCMV DNA polymerase also utilized a synthetic DNA primer containing a single molecule of CDV at the 3'-terminus. The Km value for this DNA primer-template was 165 +/- 42 nM and incorporation of dCTP was approximately 17 times more efficient than that of CDVpp. The slower rate of incorporation of CDVpp was due mostly to the higher Km value of CDVpp toward the enzyme-primer-template complexes. These data demonstrate that incorporation of a single CDV into DNA by HCMV DNA polymerase does not lead to chain termination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630098     DOI: 10.1016/0006-2952(96)00100-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Characterization of the DNA- and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Martin Bisaillon
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

2.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.

Authors:  Scott H James; Nathan B Price; Caroll B Hartline; E Randall Lanier; Mark N Prichard
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

4.  Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice.

Authors:  J C Lenzo; G R Shellam; C M Lawson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate.

Authors:  Wendy C Magee; Karl Y Hostetler; David H Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.

Authors:  D Topalis; I Lebeau; M Krecmerová; G Andrei; R Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

7.  Alkoxylalkyl Esters of Nucleotide Analogs Inhibit Polyomavirus DNA Replication and Large T Antigen Activities.

Authors:  Nichodemus O Onwubiko; Suraya A Diaz; Marcela Krečmerová; Heinz Peter Nasheuer
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 8.  Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

Review 9.  Cidofovir.

Authors:  A P Lea; H M Bryson
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

10.  Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.

Authors:  Don B Gammon; Branawan Gowrishankar; Sophie Duraffour; Graciela Andrei; Chris Upton; David H Evans
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.